Thursday, March 18, 2021 10:31:32 AM
AstraZeneca vaccine only 10% effective against variant in South Africa
Last month, South Africa halted the rollout of AstraZeneca and Oxford University’s Covid-19 vaccine after a study showed it didn’t protect against mild-to-moderate cases caused by the B.1.351 variant, which is now widespread in the country. Now we’re getting a look at the data.
While the vaccine was showing an efficacy of around 75% prior to the spread of B.1.351, a new analysis suggested the vaccine is only 10.4% effective against the variant, according to data published in the New England Journal of Medicine.
The study enrolled 2,026 HIV-negative adults, about half of whom were randomized to receive the vaccine. A total of 42 came down with Covid-19, and 39 of those cases were caused by the B.1.351 variant. Overall efficacy in this group, which consisted mostly of cases linked to the variant, was just under 22%.
“What this data don’t tell us is whether or not this vaccine might still protect at least against severe Covid-19,” Shabir Madhi, chief investigator of the study, said during a briefing last month.
Two days after halting the country’s rollout of AstraZeneca and Oxford University’s Covid-19 vaccine, South Africa’s government said it was considering selling or exchanging the doses it had already received.
https://endpts.com/covid-19-roundup-alnylam-vir-quietly-deprioritize-covid-19-drug-data-suggest-astrazenecas-vaccine-is-only-10-4-effective-against-new-variant/
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM